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Abstract:
Pseudomonas aeruginosa is a facultative anaerobic bacterium that is the most
common type of Gram-negative bacteria causing nosocomial pneumonia in the United
States. P. aeruginosa is an opportunistic pathogen ubiquitously found in the
atmosphere that can colonize both plants and animals. It is known to cause a wide
range of severe, persistent, and fatal infections ranging from acute and chronic
pneumonia, skin and soft tissue infections to urinary tract infections, especially in
immune-compromised individuals. Patients with cystic fibrosis are at high risk because
of deficiencies in mucosal immunity and phagocytosis. Ultimately, Pseudomonas
infections can be lethal. There is a very high level of antibiotic resistance in P.
aeruginosa leading to many attempts to design a vaccine. However, no licensed
vaccine has been approved or is commercially available. In this study we utilized the
tobacco mosaic virus platform delivery system to develop a vaccine against P.
aeruginosa.
The vaccine consists of the tip protein of the Pseudomonas type 3 secretion
system, PcrV, conjugated to the coat protein of recombinant TMV. We vaccinated
mice by administering 20µg of vaccine conjugate (TMV-PcrV) or 10µg of unconjugated
rPcrV in PBS by intranasal droplet (IN) to anesthetized mice. In the first experiment
mice were vaccinated on days 0, 14, and 28. In the second experiment, 2ug of dicyclic-GMP adjuvant was included in the vaccine groups and were administered on
days 0, 21, and 35. Vaccinated mice were divided into two groups of equal numbers,
each challenged IN in a model of acute pneumonia with lethal doses of P. aeruginosa
Boston 41510 (1x107 or 1x108 CFU) seven days after the final boost. Mice were
monitored daily for morbidity and mortality.
Strong total antibody response was detected in mice vaccinated with both TMVPcrV vaccine and TMV-PcrV + di-c-GMP adjuvant compared to unvaccinated mice and

xi

mice vaccinated with unconjugated rPcrV. All mice that were vaccinated without
adjuvant that were challenged with 1x10 8 CFU of P. aeruginosa succumbed to
infection, though a 2-day right shift in mean-time-to death was observed in TMV-PcrV
vaccinated mice compared to rPcrV vaccinated. TMV-PcrV vaccinated mice
challenged with 1x107 CFU had an 80% survival rate and regained their body weight
by day 2.5, while all other mice succumbed. Challenge results with mice vaccinated in
the presence of adjuvant enhanced the antibody production for both rPcrV and TMVPcrV, consequently enhancing the survival rate. These results demonstrated the
potential of TMV as a protein subunit vaccine delivery system for P. aeruginosa
antigens. Collectively, TMV conjugation induced a strong humoral immune response
and enhanced vaccine-mediated protection against P. aeruginosa in an acute
pneumonia model, providing proof of principle for a TMV-mediated vaccine against this
antibiotic-resistant nosocomial pathogen.

xii

1.0 Introduction:
1.1

Pseudomonas aeruginosa and Respiratory Infection
P. aeruginosa is the most common type of gram-negative bacteria causing

nosocomial pneumonia in the United States (Curran et al., 2018). It has been reported
that nosocomial pneumonia caused13% to 50% of mortality (Curran et al., 2018).
Pneumonia could be either hospital-acquired pneumonia (HAP) or Ventilator acquired
pneumonia (VAP) (Curran et al., 2018; Kalil et al., 2016). Furthermore, P. aeruginosa
is a ubiquitous pathogen in the environment that can colonize diverse life forms,
including plants and animals (Tümmler & Klockgether, 2017). It is an opportunistic
pathogen that survives harsh environmental conditions such as the lung. It infects
airways and causes a respiratory infection that is classified as either acute or chronic
(Gellatly & Hancock, 2013 ; Williams et al., 2010 ; Lavoie et al., 2011). This bacterial
infection generally does not infect healthy people and is only limited to patients with
immune system defects or those who are immunocompromised (Williams et al., 2010 ).
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1.1.1 Acute Pneumonia (Ventilator-Associated Pneumonia)
Ventilator-associated pneumonia is the most common infection that occurs in
the intensive care unit among critical patients. It is attributed to a significant mortality
rate of approximately 13.5%. P. aeruginosa is the prevalent causative agent of VAP.
A recent study by Micek et al.(2012) reported that Pseudomonas VAP mortality has
increased to around 41.9% in patients over the age of sixty-five (Ramírez-Estrada et
al., 2016). However, different serotypes of Pseudomonas behave differently: the
percent mortality with O6 and O11, which are the common serotypes, were lower
compared to the O1 and O2. Furthermore, the clinical resolution of O6 and O11 was
75% and 57%, respectively. On the other hand, in the less common stereotypes, O1
showed higher mortality than O2, which accounts for 40% of infection versus mortality;
meanwhile, the clinical resolution appears to be significantly better with O2 (Lu et al.,
2014). Acute nosocomial pneumonia is associated with a VAP patient whose epithelial
cells are damaged as a result of direct trauma due to the insertion of an endotracheal
tube that can be a reservoir for P. aeruginosa and cause breached epithelium (Gellatly
& Hancock, 2013). In this case, P. aeruginosa grows as biofilm, which increases its
resistance to antibiotics and disinfectants (Gellatly & Hancock, 2013 ; Williams et al.,
2010). Acute pneumonia is more likely in those who lack an efficient immune response,
including old age, or immunosuppression due to organ transplantation (Gellatly &
Hancock, 2013). In the 2005 American Thoracic Society and Infectious Diseases
Society of America guidelines, it was recommended to combine the antipseudomonal
agents' cephalosporin (cefepime, ceftazidime) and fluoroquinolone (ciprofloxacin or
levofloxacin) for treatment of P. aeruginosa VAP; however, this was inappropriate due
to inadequate dosage that was determined by Therapeutic Drug Monitoring and
suboptimal tolerance to antibiotics (Ramírez-Estrada et al., 2016). In 2013,
ceftazidime- avibactam showed efficient action in the treatment of nosocomial infection
against P. aeruginosa in the murine model. It penetrated the epithelium lining fluid and
2

produced a reduction against P. aeruginosa with minimum inhibitory concentration
(MIC) up to 32 µg/ml (Housman et al., 2014).

1.1.2 Chronic Pneumonia (CF Patient)
Chronic pneumonia is known as non-acute pneumonia, but the characteristics
that distinguish them are still unclear (Williams et al., 2010). Over the last years,
several studies have compared the detection of cystic fibrosis (CF) pathogens in lower
airways and deep throat cultures (Lyczak et al., 2002). A study that found a high
percentage of oropharyngeal culture detected the presence of Pseudomonas in lower
airways, which was determined by Bronchoalveolar Lavage (BAL) culture; a low
negative predictive value detected Pseudomonas in their BAL with negative throat
cultures (Lyczak et al., 2002). CF lung has an abnormal composition of airway
secretions that expose CF patients to chronic colonization by P. aeruginosa. These
secretions may have aberrant chloride concentration due to a cystic fibrosis
transmembrane conductance regulator (CFTR) mutation ( Lyczak et al., 2002).
Results obtained by Tager et al.(1998) demonstrated that in the presence of a
significant level of chloride concentrations, the phagocytotic activity of neutrophils is
impaired in CF patients (Tager et al.,1998). Neutrophil is considered one of the primary
cells that produces antimicrobial peptides. Once it is defective, the composition of
airway secretions consequently affects the action of antimicrobial peptides (Lyczak et
al., 2002).
In the lung, P. aeruginosa colonizes patients with CF and chronic obstructive
pulmonary disease (COPD) (Gellatly & Hancock, 2013 ; Curran et al., 2018). If P.
aeruginosa is not eliminated during acute infection, it gets adapted to the lung
environment and causes chronic infection (Gellatly & Hancock, 2013). In people who
get CF via mutation in CFTR thick airway surface liquid (ASL) is formed that in turn
3

impairs immune response and resists its stimulation (Gellatly & Hancock, 2013 ;
Williams et al., 2010). CFTR mutation could inhibit mucociliary clearance by stimulating
bacterial adhesion to airway epithelium cells (Lyczak et al., 2002). Comparing the nasal
epithelial culture of CF and non-CF patients, CF patients were found to have a higher
level of the ganglioside asialo-GM1, an epithelial cell receptor that binds to P.
aeruginosa pili (Saiman & Prince, 1993). In addition, another study examined the ability
of the (CFTR) mutation to control bacterial inflammation (Blohmke et al., 2012).
Furthermore, P. aeruginosa is associated with people who have COPD that
occurs as a result of the stretching of bronchial airways due to the destruction of
muscles and elastic tissues (Gellatly & Hancock, 2013). The influence of this chronic
inflammation of the lung is narrowing of the airways and ultimately leads to restricted
airflow (Gellatly & Hancock, 2013). Frequently, COPD patients are elderly, and
generally, their lung function is declining due to age (Gellatly & Hancock, 2013).
Ultimately, COPD can contribute to death if it is not treated, which is why it is the fourth
cause of mortality in the United States (Hurd, 2000).

1.1.3 Importance in HAI, Antibiotic Resistance, and as an
ESKAPE Pathogen
ESKAPE is a group of Gram-negative and Gram-positive bacteria that cause
nosocomial infection which could be transmitted by either direct or indirect contact
among healthcare workers, visitors, patients and contaminated objects. It is associated
with significant mortality and morbidity in the United States. In 2011, there were around
722,000 cases of ESKAPE hospital-acquired infection (HAI) and 75,000 referred to
nosocomial infection. Another survey conducted in 2002, reported approximately 1.7
million patients suffered from ESKAPE hospital-acquired infection (HAI) that
contributed to a high percentage of death. Additionally, these ESKAPE bacteria are
4

characterized by potent antimicrobial resistance that highly correlates to nosocomial
infection among immunocompromised patients (Santajit & Indrawattana, 2016).
ESKAPE pathogens show resistance to antimicrobials through several
mechanisms which makes them difficult to control (Curran et al., 2018 ; Livermore,
2002). Pseudomonas VAP isolates have been shown to be around 33% resistant to
fluoroquinolone, 30% resistant to carbapenem, and 18% were multidrug resistance
(Priebe & Goldberg, 2014). Firstly, many bacteria produce enzymes such as βlactamase which is the most predominant bacteria defense that acts irreversibly and
inactivates antibiotics by hydrolyzing the β-lactams ring present in all B-lactams
antibiotics (Jacoby & Munoz-Price, 2005). PSE-1 and PSE-4 are the most frequent βlactamase enzyme genes obtained by P. aeruginosa (Livermore, 2002). Secondly,
some bacteria such as P. aeruginosa express the impermeability outer membrane
protein function as exporters called efflux pumps; an example is the OprF gene that
mediates cell-associated pores (Benz & Hancock, 1981; Santajit & Indrawattana,
2016). The impermeability mediated resistance is reflected by the upregulation of the
efflux system such as MexAB-OprM, which is chromosomally encoded, and has a
major role in the disorganized cytoplasmic membrane, which leads to increase
resistance to many antibiotics, such as carbapenems and fluoroquinolones (Livermore,
2002; Santajit & Indrawattana, 2016).
Furthermore, the outer membrane of Gram-negative bacteria contains proteins
known as porins that form a channel to allow flowing hydrophilic substances like
antibiotics (Santajit & Indrawattana, 2016). In P. aeruginosa studies, it has been
illustrated that reducing the amount of OprD proteins (porin) leads to decreased drug
flow inside the cell, which gives resistance to bacteria against imipenem (Fukuoka et
al., 1993). Ultimately, the biofilm most likely contributes to drug-resistance by the
formation matrix of biofilm, which provides conditions that weaken the activity of the
drug (e.g., low pH, low O2 and high CO2) therefore, under these conditions it is
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challenging to clear bacteria using an antibiotic. Moreover, exposure to environmental
conditions such as biofilm growth may change gene expression resulting in the
upregulation of genes that produce resistance (Gellatly & Hancock, 2013).

1.2

Genome and Structural Components of Pseudomonas
aeruginosa

1.2.1 P. aeruginosa Genome
The completed genome of P. aeruginosa strain PAO1 has a 5.57 Mbp size and
75-67% guanine-cytosine contents. It is made of a circular chromosome plus different
plasmids (Klockgether et al., 2011). Genome sequencing was accomplished by wholegenome shotgun sequencing. Pseudomonas has the largest sequenced genome
among the 25 completed sequenced bacterial genome with 6.3 million base pairs. The
genome sequence for the bacteria gives insight into the versatility and potential drug
resistance of P. aeruginosa, as well as its biology and mechanisms of pathogenesis
(Stover et al., 2000).
Furthermore, P. aeruginosa genome contains a high percentage of regulatory
genes, transporters, transcriptional regulators, and two-component system regulatory
systems, which is consistent with its large genome and environmental adaptability
(Klockgether et al., 2011; Stover et al., 2000). More than 500 regulatory genes were
specified in the P. aeruginosa strain PAO1 and around 8.4% of genes have a
predominant role in regulation, such as the two components system and transcriptional
regulators. However, the genome sequence of PA14, revealed more virulence factors
than the PAO1 strain (Stover et al., 2000). Approximately 58 regions of PA14 were not
detected in the PAO1 strain including PA14 pathogenicity islands PAPI-1 and PAPI-2
(Klockgether et al., 2011).
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In a comparative analysis study, they compared the Pseudomonas genome
with the E. coli genome. The study illustrated that the large genome of Pseudomonas
is due to the complexity of genes and not to the differences in genome organization.
Additionally, they identified the largest repeats in the Pseudomonas genome that
appeared in four ribosomal DNA loci and one duplicated gene that extended through
a thousand base pairs. Moreover, compared with other bacterial genomes, they found
that the Pseudomonas genome contains more diverse paralogous genes, around 50%
than other bacteria. Interestingly, 372 open reading frames (ORFs) were identified in
the Pseudomonas genome as functional genes that primarily encode for
exopolysaccharide enzymes, virulence factors, and other proteins involved in adhesion
and motility (Stover et al., 2000). Each exopolysaccharide (Psl, Pel, and Alginate) is
encoded on a different region in the genome (Franklin et al., 2011).
Around 150 genes encode for outer membrane proteins (OMPs), which is
considered a large number compared to other genomes; 34 genes are involved in ironsiderophore uptake and ten genes encode for Efflux pumps. Furthermore,
Pseudomonas has a large efflux system which accounts for ten genes as compared to
E. coli that has only four genes. Exceptionally, the only known sequenced bacteria that
has a large number of genes encoded for outer membrane proteins (OMPs) is H. pylori.
The identification of OMP family could be a considerable impact on the vaccine and
antimicrobial research (Stover et al., 2000). In addition to these, the Pseudomonas
genome has the most complicated chemosensory system among all sequenced
bacterial genomes, which is illustrated in the four loci involved in chemotaxis signal
transduction (Stover et al., 2000).

7

1.2.2 P. aeruginosa Lipopolysaccharide
Lipopolysaccharide (LPS) is a complex glycolipid that makes up the outer
membrane of Gram-negative bacteria. It is considered one of the most important
virulence factors(Pier, 2007) that acts as a physical barrier by direct interaction with
host immune response, antibiotics, and host cell receptors (King et al., 2009). LPS is
composed of three domains: Lipid A, Core oligosaccharide, and O-specific antigen
polysaccharide (O-A)(King et al., 2009; Gellatly & Hancock, 2013; Pier, 2007).
Furthermore, P. aeruginosa produces two forms of O antigen. The first is a
homopolymer of D-rhamnose (D-Rha), known as A band or common O
polysaccharide, which is approximately 70 sugars long and elicits a weak antibody
response (King et al., 2009; Gellatly & Hancock, 2013). The second is a heteropolymer
of different distinct sugars in its repeat unit that is called B band (King et al., 2009; Lam
et al., 2011). Conversely, this O-specific antigen produces a strong antibody response
(King et al., 2009).
Lipid A and O polysaccharide are the two components of LPS that contributed
the most to P. aeruginosa infection (Gellatly & Hancock, 2013). Lipid A is comprised
of a diglucosamine biphosphate backbone with O- and N-linked primary and secondary
fatty acids (Gellatly & Hancock, 2013). It has Penta or Hexa acylated form within 1214 carbons in length (King et al., 2009; Pier, 2007). During the P. aeruginosa infection,
recognition of LPS by Toll-Like Receptor (TLR4) occurs via binding lipid A to the host
cell coreceptors (LPS-binding protein (LBP), CD14, and MD-2).(Gioannini & Weiss,
2007) to initiate the NF-κB signaling pathway, which triggers pro-inflammatory
cytokines and chemokines and eventually causes endotoxic shock (King et al., 2009;
Gellatly & Hancock, 2013). It has been shown that lipid A elevates IL8 expression via
recognition of LPS by TLR4 (Hajjar et al., 2002). Compared to enterobacterial, the
inflammatory response elicited by lipid A in P. aeruginosa is considered low (King et
al., 2009). On the other hand, the dominant role of O-specific antigen is to protect
8

bacteria from being engulfed by phagocytosis (Dasgupta et al., 1994), as well as to
protect against oxidative stress (Berry et al., 2009). Moreover, it has been reported that
O polysaccharide has a notable engagement in surface attachment (Abeyrathne et al.,
2005).

1.2.3 Alginate Capsule
Pseudomonas alginate is first synthesized as a linear of acidic polymer
consisting of D-mannuronic acid (Franklin et al., 2011).It is modified in the periplasm
by the action of O- acetylation and other proteins (e.g. AlgJ, AlgI, AlgF), which have
converted D-mannuronic acid to l-guluronic acid by AlgG at the polymer level. Alginate
ultimately becomes a linear of acidic polymer consisting of D-mannuronic acid and lguluronic acid (Rasamiravaka et al., 2015).
Acetylation can occur at the hydroxyl groups of either the C2 and/or C3
positions. This modification distinguishes Pseudomonas alginate from other
exopolysaccharides such as Psl and Pel as well as from the E. coli capsule (Franklin
et al., 2011). In vitro assays showed a high level of alginate exists in the cell envelope,
which demonstrated that both the inner and outer membrane were essential for
alginate biosynthesis (Remminghorst & Rehm, 2006). This result is evidence of the
multiple protein interaction around the 13 alginate form a complex that extends through
the inner membrane, periplasm and the outer layer (Franklin et al., 2011).
More experiments have proved that a multi-protein biosynthetic system exists
for alginate biosynthesis. In 1998, a study by Jain and Ohman studied the phenotypes
of periplasmic proteins (AlgK, AlgX, and AlgG). They found that the deletion of one of
these genes resulted in the release of unpolymerized uronic acid subunits, which are
assumed to have been degraded by alginate AlgL (Franklin et al., 2011; Flynn &
Ohman, 1988). These genes are a part of the biosynthetic complex; otherwise, the
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synthetic polymer is degraded by AlgL if the complex is not present (Franklin et al.,
2011). In 1993, another study concluded that the deletion of cytoplasmic proteins (Alg8
and Alg44) resulted in no alginate production, which is in contrast to periplasmic
proteins. Therefore, Alg8 and Alg44 are required for alginate polymerization (Franklin
et al., 2011; Maharaj et al., 1993).
Alginate is a high molecular weight protein (Franklin et al., 2011). It has a
predominant role in biofilm stability and protection. Alginate also aids in the
maintenance of water and nutrients (Rasamiravaka et al., 2015). The significance of
alginate in the pathology of CF has resulted in being the first exopolysaccharide
defined and it remains the best characterized P. aeruginosa exopolysaccharide
(Franklin et al., 2011). Moreover, alginate biosynthesis does not require lipid presence,
which makes it similar to bacterial cellulose synthesis (Römling, 2002).

1.3

Lifecycle of Pseudomonas aeruginosa
Pseudomonas biofilm formation aggregates bacterial communities together in

a matrix of extracellular polymeric substances (EPS) on a surface (Rasamiravaka et
al., 2015). The regulation of biofilm formation is controlled by the quorum-sensing
system (Gellatly & Hancock, 2013; Moradali et al., 2017) where different biofilm can
be developed depending on the nutritional factors as well as Pseudomonas strains
(Shrout et al., 2006). Biofilm formation by P. aeruginosa (PAO1) is achieved through
five stages. It starts with reversible adhesion, which occurs by planktonic bacterial cells
attaching to a site to get ready for growth (stage I). This is followed by stage II:
maturation and growth occur by irreversible attachment of bacteria and formation of
microcolonies in the EPS matrix, which then mature to multi-layered cells. In stage III,
microcolonies start to extend and form a more structured phenotype in a non-colonized
space. Thereafter, the non-colonized space fills with bacteria until the total surface
10

area is covered (stage IV). Finally, in stage (V) the bacteria scatter and detach then
reenter a planktonic state to settle other surfaces (Santajit & Indrawattana, 2016;
Rasamiravaka et al., 2015). Detachment can happen either actively, initiated by
bacteria itself, or passively which is caused by outside forces (Santajit & Indrawattana,
2016).
Interestingly, Pseudomonas polysaccharides (Psl and Pel) contribute to biofilm
stability and persistence (Ryder et al., 2007) and act as a primary structure of biofilm
development, which is involved in the early stage of biofilm formation (Colvin et al.,
2011). Besides polysaccharide, alginate takes part in holding biofilm cells together on
the EPS matrix (Ryder et al., 2007). Several studies have demonstrated the role of
extracellular DNA in biofilm formation since bacteria that lack eDNA are more sensitive
for degradation by detergent sodium dodecyl sulfate (SDS). eDNA plays an important
role in protecting biofilm against DNase I and is a source of nutrients for bacteria during
starvation (Rasamiravaka et al., 2015).

1.4 Virulence Factors of Pseudomonas aeruginosa
A previous study revealed that P. aeruginosa isolated from acute infection has
a different phenotype than chronic infection (Smith et al., 2006). Moreover, genetic
characteristics of the bacterial cell that presents in the early phase of chronic infection
in CF patients are distinct from those that initiate the infection later (Hogardt &
Heesemann, 2010; Smith et al., 2006). What is clear is that virulence factors influence
the severity of infection (Gellatly & Hancock, 2013). Several bacterial factors alter
immune-inflammatory effects that are reduced during the switch from acute to chronic
infection, such as pili and flagella.(Smith et al., 2006; Nguyen & Singh, 2006). The P.
aeruginosa isolated from acute infection generally express more virulence factors than
those isolated from chronic infection (Gellatly & Hancock, 2013).
11

The type III secretion system is the major virulence determinant in
Pseudomonas, which impacts cell cytotoxicity. The PcrV is located at the tip of the
T3SS needle, which resembles a molecular syringe. Upon contact with host cells it can
transport multiple virulence factors directly into host cells. Developing antibodies
against PcrV prevents T3S-mediated cytotoxicity (Tabor et al., 2018)
Furthermore, the type III secretion system is downregulated in chronic CF P.
aeruginosa infection (Hogardt & Heesemann, 2010). Effector proteins are secreted by
the type III secretion system :ExoS, ExoT, and ExoU, which affect actin cytoskeletal,
block reactive oxygen species and cause rapid death of host cell, respectively (Kipnis
et al., 2006; Tümmler & Klockgether, 2017; Hauser, 2009).
OprF is an outer membrane porin of Pseudomonas aeruginosa. Based on the
comparative study of wild-type and isogenic oprF mutant of P. aeruginosa, OprF is
required for P. aeruginosa virulence. The absence of OprF results in impaired adhesion
to animal cells, secretion of ExoT and ExoS toxins through the T3SS, and production
of the quorum-sensing-dependent virulence factors (Fito-Boncompte et al., 2011). The
small and abundant OprI lipoprotein was also shown to be involved in cell shape and
maintain outer membrane stability. An oprI mutant produced a higher outer membrane
vesicle than the wild-type strain, however its Pseudomonas quinolone signal (PQS)
production was unaffected. This indicates that the absence of OprI stimulated OMV
biogenesis by reducing the outer membrane tethering to peptidoglycan. Conversely,
OprF mutant of PA14 led to the higher OMV biogenesis level as a result of an increase
in PQS production(Chevalier et al., 2017).
A recent study has shown that in chronic CF P. aeruginosa infection the
bacteria has a deficiency in pili and flagella which are required to initiate colonization.
This aids bacteria in avoiding immune recognition as well as clearing by phagocytosis
(Hogardt & Heesemann, 2010). In mutagenesis studies, a mutation in the rpoN gene
led to the loss of both flagella and pili (Hogardt & Heesemann, 2010).
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Several proteases secreted by P. aeruginosa have a major role in degrading
immunoglobin by cleavage the Fc region of antibodies,(Kipnis et al., 2006), host
complement protein(Gellatly & Hancock, 2013; Tümmler & Klockgether, 2017)
(Laarman et al., 2012) and disrupt tight junction in epithelial cells (Kipnis et al., 2006).
Additionally, they inhibit recognition by alveolar macrophages, which promote
intracellular survival (Gellatly & Hancock, 2013; Malloy et al., 2005). Taken together,
P. aeruginosa has diverse effector proteins that contribute to its pathogenicity.

1.5

Pseudomonas aeruginosa Vaccine Development

1.5.1 P. aeruginosa Vaccines for CF patients
P. aeruginosa appears in multiple infections, including CF patients (Gellatly &
Hancock, 2013; Curran et al., 2018; Pier et al., 1987). CF is a recessive genetic
disease that is susceptible to chronic lung infections by P. aeruginosa which is driven
by multiple factors (Priebe & Goldberg, 2014). One factor is related to the CFTR
mutation that enhances bacterial entry and causes bacterial clearance to fail (Priebe
& Goldberg, 2014; Lyczak et al., 2002). Others are disturbed in mucosal immunity and
the defective mucociliary system, which is caused by forming odd viscous secretions
(Priebe & Goldberg, 2014). In the mid-1980s, Pier and colleagues were exploiting
resistant mechanisms of P. aeruginosa by studying serum from patients with CF and
healthy adults. The sera were taken from different volunteers: CF patients colonized
with mucoid P. aeruginosa, CF patients not colonized with mucoid P. aeruginosa, and
healthy individuals (Pier et al., 1987). They found that CF patients who were colonized
with mucoid P. aeruginosa had a high level of opsonophagocytic antibodies against
the alginate capsule compared to non-colonized patients (Pier et al., 1987). The
phenotype of P. aeruginosa is variable depending on the CF disease progression. A
study that isolated P. aeruginosa from early and late CF patients concluded that
isolates taken from early CF patients were characterized as non-mucoid with smooth
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LPS, while samples isolated from late CF patients were mucoid with rough LPS
(Hancock et al., 1983). Furthermore, a study testing efficiency of opsonizing antibody
by Pier, Small, and Warren in rodent models concluded that mice and rats immunized
with mucoid exopolysaccharide (MEP) stimulated production of opsonizing antibodies.
These immunized rodents had reduced P. aeruginosa bacteria after intratracheally
challenge with mucoid P. aeruginosa compared to control groups (Pier et al., 1990).
However, the defense mechanism of opsonizing antibody is not obvious, especially in
early CF chronic infections known as non-mucoid LPS (Priebe & Goldberg, 2014).
Interestingly, the synthetic monoclonal antibody, which is designed specifically to
carbon 6 of mannuronic acid of Pseudomonas alginate, confers protection in an acute
pneumonia mice model and is accompanied by phagocyte killing mucoid and
nonmucoid strains (Pier et al., 2004).
There was a vaccine developed by Doering, Meisner, Stern, called bivalent
flagella that was in phase III trials. Patients were given four intramuscular doses of
bivalent flagella vaccine for a 14-month period. Then they evaluated the patient's sera
for two years. During that time, patients developed a high and well-tolerated titer of
antiflagellum IgG and other antibody types specific to flagella (IgA and secretory IgA).
Subsequently, the bivalent flagella vaccine reduced P. aeruginosa by at least 66% in
CF patients (Döring & Pier, 2008; Döring et al., 2007). Unfortunately, the company
stopped producing this vaccine before the end of the trial, and no other companies
have taken over production of the flagella vaccine (Priebe & Goldberg, 2014).
Another trial of a flagella vaccine occurred in which, they conjugated the
flagella vaccine with poly mannuronic acid (PMA) that has an epitope that could be
recognized by a monoclonal antibody. This vaccine showed protection only against
mucoid strains by producing opsonic antibodies (Priebe & Goldberg, 2014). However,
the antibodies made by the flagella vaccine showed no neutralizing activity on TollLike Receptor 5 (TLR), which is an essential part of stimulating innate immune
response to flagellated bacteria (Campodónico et al., 2011).
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1.5.2 Live Attenuated Vaccines
Research has focused on the mechanism of attenuation to develop robust
vaccines against lethal pneumonia infections caused by Pseudomonas aeruginosa. In
a mutagenesis study, Pseudomonas PA14 mutant Aro gene, which is required for
aromatic amino acid synthesis, showed a highly immunogenic response and was
attenuated for lung infections in a murine model (Priebe & Goldberg, 2014). A study
that exploited a live attenuated vaccine based on the PA14 strain showed that Aro
deleted PA14 or ∆aroA; immunized mice had high levels of early neutrophil recruitment
to the airway post-infection compared to control mice. Moreover, T cells isolated from
the immunized mice were proliferative and were accompanied by large quantities of
IL-17 production in bronchoalveolar lavage fluid. Notably, the absence of IL-17
receptor abrogated this vaccine's protection (Priebe et al., 2008).
Additionally, mice and rabbits vaccinated with PAO1 ∆ aroA intranasally
produced a high level of IgG response. The rabbit antisera enhanced phagocytic killing
of PA heterologous strains and O2\O5, strains whilst mouse antisera mediated killing
of serotype O2\O5 strains (Priebe et al., 2002). A different study used the
neutropenic mouse model, which were immunized intranasally by live attenuated ∆
aroA vaccine against P. aeruginosa. Many macrophages and monocytes recruited
post-infection served as potent effector innate cells after immunization. Additionally,
this was accompanied by a high proportion of CD4 T cells in the lung and spleen, which
enhanced clearance of P. aeruginosa from the lung. Thus, this study showed that
mouse model immunity induced by mucosal P. aeruginosa live attenuated vaccines
was protective even when neutrophils are deficient (Kamei et al., 2013).
Another study by Kamei et al. (2011) approached multivalent live attenuated
vaccines ∆aroA in a mouse model of acute pneumonia. The vaccine contains four
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attenuated Pseudomonas strains with different LPS serogroups. This vaccine was
efficacious to protect against P. aeruginosa lung infections and resulted in local CD4
T cells in the lung as well as an opsonic antibody against LPS core and other surface
proteins (Kamei et al., 2011).

1.5.3 Killed Whole Cell Vaccines
Pseudomonas vaccines using killed bacteria have been prepared by several
techniques, such as treating P. aeruginosa cells with paraformaldehyde to inactivate
the bacteria (Cripps et al., 1994; Buret et al., 1993). A study done in 1992 investigated
the efficiency of immune clearance of bacteria in rat lung. Rats were immunized with
killed a mucoid strain of P. aeruginosa. After challenging rats with live bacteria
intratracheally, a high level of anti-Pseudomonas antibodies was present in the
vaccinated rats' sera (IgG, IgA, IgM) and bronchoalveolar lavages (IgG and IgA). In
addition, bacterial clearance was significantly accelerated in the lung of all immunized
rat models. Moreover, this study found improvement in recruitment, chemotaxis,
chemokinesis, and post-infection phagocytic activity of PMN. Notably, in the alveolar
space of immunized rats, a high proportion of polymorphonuclear neutrophils (PMN)
were observed. The increase of PMNs did not correlate with increased leukotriene B 4
(LTB4), a pathway important in the pathogenesis of neutrophilic inflammation that
coexists at sites of inflammation and tissue remodeling. In contrast the level of PMN
recruitment was lower in unimmunized versus immunized rats and associated with
elevating leukotriene B4 in alveolar space (Cripps et al., 1994).
Similarly, a study by Cripps et al. (1993), determined the efficiency of mucosal
and systemic immunization with inactivated Pseudomonas aeruginosa against acute
respiratory infections in rat models. The rats were immunized with paraformaldehyde
killed P. aeruginosa, then were challenged with live Pseudomonas bacteria. The dose
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was lethal to the unimmunized rats 12 hours post challenge. They determined the
number of surviving bacteria in the immunized rats by analysis of bronchoalveolar
lavage fluid (BAL) and lunge homogenate samples 4 hours after challenge. The results
showed significant bacterial clearance in immunized rats compared to the bacterial
burden in unimmunized models (Buret et al., 1993).
This kind of vaccine may be a favorable approach to use as an oral formulation
for infants with CF to avoid or postpone P. aeruginosa colonization (Cripps et al.,1994).

1.5.4 Subunit Vaccines
Ongoing studies of subunit vaccine development have identified many antigens
that are able to induce partial protection against P. aeruginosa. Some vaccine
strategies have focused on outer membrane proteins (OMPs), OprF and OprI, which
are conserved among all Pseudomonas strains and required for adhesion to the host
cells as well as OprF\OprI fusion or hybrid proteins (Priebe & Goldberg, 2014). In 1995,
Hughes and Gilleland tested three different synthetic peptides presenting the epitope
of OprF of Pseudomonas in acute murine models (Hughes & Gilleland, 1995).
Synthetic peptides 9, 10 and 18 were each conjugated to keyhole limpet hemocyanin
(KLH) which is highly immunogenic for T cell antigens. Mice immunized with peptide
9, 10, and 18 showed high levels of stimulating IgG and had a greater survival rate
compared to control groups. Thus, these synthetic peptides showed a potential
protection against acute pneumonia in murine models which could be considered for
further studies (Hughes & Gilleland, 1995).
Recombinant OprF/I fusion protein has been tested and induces significant
levels of specific opsonic IgG antibody (Westritschnig et al., 2014) and induced IFN-γ
CD4 and CD8 responses (Priebe & Goldberg, 2014). Likewise, Specht et al. showed
that recombinant OprF/I hybrid protein protected immunodeficient mice against a 50%
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lethal dose of P. aeruginosa. Additionally, OprF\OprI fusion protein was used
separately to immunized rabbits and the immune rabbit sera protected severe
combined immunodeficient (SCID) mice against fatal doses of P. aeruginosa (Von
Specht et al., 1995). Taken together, active and passive immunization can protect
SCID and neutropenic mice against 50% lethal doses of P. aeruginosa (Priebe &
Goldberg, 2014).
Wu et al. (2012) identified Th17 stimulatory proteins of P. aeruginosa and then
tested their activity against lethal PA pneumonia. They identified four Th17 stimulating
proteins and three His tagged proteins purified from protein libraries from splenocytes
of mice immunized with live attenuated ∆ aroA vaccine with their protection based on
Th17 production (Priebe et al., 2008; Wu et al., 2012). OprL, PopB, and FpvA
enhanced the production of Th17 in PA14 Δ aroA-immune splenocytes (Priebe &
Goldberg, 2014). Mice were immunized with PopB intranasally, a known virulence
factor that is a highly conserved component of the type III secretion system. It elicited
a strong IL-17 response when mixed with the beta-D-glucan curdlan a known Th17
eliciting adjuvant (Priebe & Goldberg, 2014; Wu et al., 2012). The results showed the
protection of immunized mice from PA pneumonia was associated with IL-17 in the
absence of an opsonic antibody (Wu et al., 2012).
Recently in 2018, a study generated artificial PcrV derivative (PcrV NH) by
dividing full-length PcrV to four domains (Wan et al., 2019). N-term (Met1-Lys127) and
H12 (Leu251-Ile294) domains were linked together via a linker to generate artificial
PcrVNH. Immunizing mice with PcrVNH intramuscularly conferred a wide protection in
the pneumonia of the acute models with the same functionality of full-length PcrV.
Moreover, immunized mice with PcrVNH induced Th1, Th2, Th17 and high levels of
IgG1, IgG2a, IgG2b in immunized mice sera where IgG2a or IgG2b induces Th1
immune response. In addition, IFN-γ and IL-17A were observed in the spleen, which
suggests the induction of Th1 and Th17. IL-4 cytokines were detected in the spleen as
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well with high levels that subsequently induce a Th2 immune response. Interestingly,
PcrVNH immunized mice recover faster (within 120 hours post challenging) compared
to unimmunized mice (Wan et al., 2019).
Ultimately, a notable reduction of pro-inflammatory cytokines, such as TNF-α
and IL1β were detected in PcrVNH immunized mice (Wan et al., 2019).

1.5.6 Therapeutic antibody
It may not be possible to achieve the time or role of the immune system needed
to develop an effective response to active vaccination. Thus, there have been multiple
attempts to develop an antibody-based therapy for eliminating a Pseudomonas
infection or preventing the disease.
Anti-P. aeruginosa IgY showed high activity in hindering P. aeruginosa
attaching to epithelial cells (Priebe & Goldberg, 2014). Anti-P. aeruginosa IgY is
generated by vaccination of laying hens that produce specific IgY transferred to egg
yolk in large quantities (Priebe & Goldberg, 2014; Carlander et al., 2000). It has been
reported that laying hens can produce more than 20g of yolk antibodies per year. The
advantage of using yolk antibodies is they cannot either bind to the Fc receptor or
activate the human complement system which both lead to an inflammatory response.
Importantly, many studies have shown the efficacy of yolk antibodies in protection
against bacterial and viral infections (Carlander et al., 2000).
Furthermore, Anti-O11 mAb was generated by vaccination of volunteers with
early octavalent O-polysaccharide-toxin A conjugate vaccine. This human antibody
was specific against P. aeruginosa serotype O11 O polysaccharide, which indicated
the specificity of the response. In animal studies using Pseudomonas infected mouse
models, this monoclonal antibody showed opsonophagocytic activities against P.
aeruginosa serotype O11, protection against the bacteria in burn wounds, including
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reduced numbers of bacteria and a notable reduction in lung injury; however, it did not
provide complete protection in serotype O11. As expected, it showed no reduction
against non-serotype O11 (Horn et al., 2010). A study that generated an artificial PcrV
derivative tested the efficiency of anti -PcrVNH antibodies against PA infections. The
presence of anti -PcrVNH exhibited a potent opsonophagocytic activity, and the level of
secreted ExoU was decreased by increasing anti -PcrVNH antibodies. In addition, this
antibody has a significant effect on T3SS mediated cytotoxicity by inhibiting its action
(Wan et al., 2019).

1.6 Models for Cystic Fibrosis Studies and Chronic Infections
with P. aeruginosa
1.6.1 Animal Model
In the past few decades, many mouse models have been created by using the
targeted distruption of gene sequences within embryonic stem cells (Kukavica-Ibrulj &
Levesque, 2008). Interestingly, mouse models are still different from humans due to
several factors: mutation types, mRNA expression level, and the genetic background
of the mouse strain. Eventually, a mixed genetic background including chromosomes
from the mutant embryo stem cell line and the recipient blastocyst (FVB or C57BL/6)
become available in CF mouse models today (Kukavica-Ibrulj & Levesque, 2008).

The first CF murine model was described by Snouwaert et al. (1992) at the
University of North Carolina after the characteristics of CFTR gene were defined. They
successfully generated a CFTR knockout (CFTRtm1UNC) mouse from embryonic stem
cells by insertion of a stop codon in exon 10 of the CFTR coding sequence, known as
the S489X mutation. This model was used as a basis by other scientists to generate
various knockout models, such as (CFTRtm1CAM) and (CFTRtm1HSC). In addition, knock-
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in mutants were developed. Different mutations that causes CF were introduced to the
endogenous mouse CFTR gene to produce mice carrying the Class II ΔF508
(CFTRtm1EUR, CFTRtm1KTH, and CFTRtm2CAM) and G480C (CFTRtm2HGU) mutations.
However, it has been reported that there was intramutant variation in the disease
severity, survival and pathology of these animals (Lavelle et al., 2016).
Currently used mouse models contain various phenotypes of CF mutation
including complete knock out (KO) of CFTR function, CFTR dysfunction, and the exact
mutation found in human CF. The complete KO of CFTR and residual CFTR function
mouse models resulted in total loss of CFTR function; with no CFTR protein produced
examples are CFTRtm1Unc and CFTRtm1Bay(Kukavica-Ibrulj & Levesque, 2008).
Agar-bead (chronic) pneumonia model used extensively in CF research and
was originally developed in rats. They used agar or seaweed alginate beads as
extracellular polymeric substances to mimic biofilm. The beads are loaded with
bacteria in a process that requires mixing with mineral oil and emulsifying agent,
sorbitan-monooleate, to increase the consistency of the beads (Bielen et al., 2017). In
1987, Starke et al., modified the first agar bead model to use in mice. Subsequently,
this model has been used frequently to study CF lung disease and bacterial infections.
Moreover, different CF mouse models were developed using gene targeting to disrupt
murine CFTR locus through homologous recombination and to introduce a specific
human mutation into mouse loci, such as ∆F508 (Kukavica-Ibrulj & Levesque, 2008).

On the other hand, the first rat model was designed by Cash in 1979 using P.
aeruginosa embedded in agar beads for bronchopulmonary infections. The aim was to
maintain the existence of bacteria in the airways to allow it to mimic bacterial biofilm in
CF lungs. Recently, it has been proved that the presence of P. aeruginosa within agar
beads is more characteristic of CF than the administration of P. aeruginosa alone.
Interestingly, bacterial growth is shown to be slow within agar bead which is parallel to
what is observed in biofilm formation and in the planktonic state. Moreover, a study
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conducted in 2005 showed that an alginate capsule could be used as an alternative of
an agar bead since it mimics normal conditions of CF in a lung where bacteria are
embedded with alginate (Kukavica-Ibrulj & Levesque, 2008).
For acute pneumonia, a one hit acute pneumonia model is established by
administering a bacterial inoculum into the lungs using different methods of bacterial
delivery. Intratracheal installation is the most used method in HAP research, which
involves injecting the bacterial suspension directly into the trachea or lungs followed
by air for dispersion of the tablet. Second, endotracheal inoculation requires intubating
the animal to facilitate the installation of the bacterial solution in the lungs. Ultimately,
intranasal administration was done by administering bacterial dose in droplets through
the nostrils (Bielen et al., 2017)
Other animals are also used in various studies of P. aeruginosa virulence and
in the CF area in general. An example is the cat model of chronic pulmonary infection
with P. aeruginosa, which showed similar results to human CF macrophage stimulation
and inflammation (Kukavica-Ibrulj & Levesque, 2008). Another model simulates an
invasive infection of large-area burn wounds, where animals receive a burn injury on
their back, followed by intradermal injection of the bacterial inoculum. This model has
been used widely in burn infection studies, such as bacterial translocation, gene
therapy, and antibiotic efficacy studies (Maura et al., 2018). Additionally, sheep, pigs
and cats could be used as models to understand the role of submucosal glands found
only in the proximal trachea in mice (Joo et al., 2001).
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1.6.2 Non-Mammalian Models
Alternative, easy, ethical and less costly experimental models are still needed
to understand the virulence of bacterial lung diseases. Non-mammalian models would
be appropriate to explore the pathogen-host interaction, such as the vertebrate
zebrafish (Daniorerio) and non-vertebrate insects and nematodes (e.g. Caenorhabditis
elegans). In 2009, the zebrafish embryo model was developed by Brannon et al., to
explore systemic P. aeruginosa infection as well as evaluate the type III secretion
system (T3SS) mutant. The results showed that T3SS and quorum sensing is required
for lethal infection with P. aeruginosa. Interestingly, T3SS was associated with the
initiation of infection in CF patients and elevated risk in hospitalized patients. Another
study using zebrafish as infectious models by Phennicie et al. in (2010) studied the
role of CFTR in the innate immune response to acute Pseudomonas infection (López
Hernández et al., 2015).
Using zebrafish as a model has various characteristics. Firstly, when embryo
zebrafish are used, a short time is needed because they develop very rapidly.
Secondly, only a single bacterial dose is required to initiate the pathogen population,
which is like an infection in mice models. Thirdly, the time frame of zebrafish infection
proceeds within days rather than weeks to months. In addition, the zebrafish model
allows for the chemical screening of antimicrobial compounds. However, adult fish are
less susceptible hosts for bacterial infection, so a higher dose of live bacteria 5 x 10 7
is required (López Hernández et al., 2015).
In 1999, Tan et al. used C. elegans for the first time to explore Pseudomonas
pathogenesis. They illustrated that the accumulation of P. aeruginosa cells in intestines
is important in clarifying killing mechanisms. Moreover, insects were used as host
models to identify Pseudomonas virulence factors in mammalians in this previous
study. Boman et al. (1972) concluded that P. aeruginosa is virulent in fruit flies.
Eventually, using D. melanogaster as a model helped to identify the human anti23

microbial peptide that inhibited the initiation of biofilm formation, which could be used
to develop new therapeutics for P. aeruginosa infections in the future (López
Hernández et al., 2015).

1.7

Immune Response Following P. aeruginosa Infection

1.7.1 Innate Immune Response
During the development of a pulmonary P. aeruginosa infection, bacteria evade
innate immune cells in order to colonize and infect the host successfully. The first line
of defense that counters microbes are the epithelial cells, which perform a major role
in innate immune response against infectious pathogens and serve as a physical
barrier (Gellatly & Hancock, 2013; Perl et al., 2002). Furthermore, these cells act as
sentinels to alert the innate and adaptive immune system about the infection by
expressing a number of immunoregulatory membrane receptors, and intracellular
danger sensors and their downstream effectors (Perl et al., 2002). Ciliated epithelial
cells constitute around 50% of the epithelial surface in the trachea; they push the
infectious agent out of the lung to the throat by using their cilia (Gellatly & Hancock,
2013; Knight & Holgate, 2003). Mucin one of the secreted epithelium surface
components, is located on the airway epithelium to trap and eliminate inhaled foreign
microorganisms. Depending on the variety of its structure and physical properties,
mucin has two distinct classes that perform different functions (Williams et al., 2006).
Other molecules are secreted by the epithelial cells, such as cytokines and
chemokines upon activation via Toll-like receptors (TLRs), to recruit and activate the
innate and adaptive immune cells (Gellatly & Hancock, 2013). In mutagenesis studies,
it has been reported that a deficiency in the CD59\CD59 ligand, mediated-cell death,
inhibit apoptosis of lung epithelial cells in vivo and in vitro (Grassme et al., 2000).
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During the infection, phagocytic cells, either neutrophils or macrophages, play
a prominent role in clearing a P. aeruginosa infection (Curran et al., 2018). Massive
recruitment of neutrophils into the infected airway occurs by the production of
chemokines (Lavoie et al., 2011) IL8 in human and KC in mice which is a member of
CXCR family (Gellatly & Hancock, 2013). Upon the binding of chemokines to the
CXCR2 receptor, neutrophils migrates into the site of inflammation and the
chemokines' receptor CXCR1 induces reactive oxygen species to clear bacteria
(Tümmler & Klockgether, 2017). CXCR1 is a novel non-canonical chemokine receptor
that regulates the response of anti-Pseudomonas neutrophils by modulating reactive
oxygen species and interfering with TLR5 expression (Carevic et al., 2016). A previous
study revealed that mice, which were administrated with a monoclonal antibody (anti
CXCR), inhibited neutrophils recruitment by 50% (Gellatly & Hancock, 2013; Curran et
al., 2018). Neutrophils recruitment depends on β2 integrin (e.g. CD11b/CD18, CD3)
(Lavoie et al., 2011).
Macrophages are important during Pseudomonas infection (Gellatly &
Hancock, 2013). MCP-1 cytokines are secreted by alveolar epithelial cells which in turn
stimulate macrophage migration and phagocytosis (Lavoie et al., 2011). Macrophage
phagocytize microbes and sequester antigen, (Gellatly & Hancock, 2013) then secrets
cytokines (TNF-α and IL-6) and chemokines (KC) (Lavoie et al., 2011) which enhance
neutrophil recruitment (Lavoie et al., 2011). Additionally, macrophages opsonize dead
neutrophils (Lavoie et al., 2011). One study illustrated that MCP-1 deficient mice had
reduced bacterial clearance and elevated lung tissue-damage (Kannan et al., 2009).
Upon infection, P. aeruginosa induces (NLRP3) inflammasome, which leads to
macrophage secretion of caspase-1 and interleukin 1β (Deng et al., 2015).
During bacterial clearance, inflammation should be controlled and limited or
otherwise it causes organ damages (Tümmler & Klockgether, 2017). Cytokine IL-17
serves as a balance between host response and the inflammation that triggers organ
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injuries. In the lung IL-17 A is released by many T-cell subtypes, innate lymphoid cells,
and macrophages. Once released, it activates airway epithelium to release IL-17C,
which in turn produces neutrophilic cytokines from the alveolar epithelium and expand
inflammation. Proinflammatory neutrophilic cytokines act as priming agents for
neutrophils, e.g., (IL-1 and TNF-α). These cytokines have been shown to expand
neutrophil function. IL-17C production is directly induced upon P. aeruginosa infection
(Wolf et al., 2016). The NKGD2 receptor is expressed by variety of immune cells,
including natural killer cells (NK), which prime the immune system’s responses to
infectious particles (Lavoie et al., 2011).

1.7.1.1 Cytokines and Chemokines in Host Defense
Many cytokines are produced in response to a Pseudomonas infection; the
major cytokines produced by macrophages and epithelial cells in the lung is TNF-α,
which favors the elimination of P. aeruginosa. In a mutagenesis study, mice lacking
TNF-α had difficulty eradicating a Pseudomonas infection (Williams et al., 2010). TNFα is primarily produced by bone marrow-derived cells in the MyD88-dependent
pathway following P. aeruginosa acute pulmonary infection. Moreover, TNF-α can
produce anti-inflammatory cytokines, such as IL-10. IL-10 is produced late (24 h) after
acute P. aeruginosa pulmonary infection, at a time when the levels of pro-inflammatory
cytokines and chemokines are reduced (Williams et al., 2010; Lavoie et al., 2011).
Also, TNF-α positively regulates anti-inflammatory molecules through TNFR1, such as
Muc1, that has a role in suppressing TLR. Muc1 −/− mice have a high inflammatory
response to Pseudomonas aeruginosa compare to wild type (Ueno et al., 2008).
Additionally, Muc1 is induces apoptosis in neutrophils (Williams et al., 2010; Lavoie et
al., 2011). A study on Muc1 knock out mice showed increases in the recruitment of
neutrophils in airways and accelerated bacterial clearing (Lavoie et al., 2011).
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The role of IFN-γ is less clear, when administrated exogenously mice had
enhanced bacterial clearance; however in mice deficient with IFN-γ receptor also
showed enhanced bacterial clearance ( Williams et al., 2010). IL-4 is a product of the
Th2 lymphocyte population, which stimulates B cell activation and antibody production
against P. aeruginosa (Williams et al., 2010). Mice with overexpression of Interleukin
4 eliminate bacteria in a short period of time post-infection (Jain-Vora et al., 1998). In
addition to these, Interleukin 8 is a human chemokine (CXCL8), and (KC and MIP2 in
mice) are activated by TLR upon stimulation with Pseudomonas. It plays a primary role
in the migration of neutrophil and otherwise causes a defect if there is no neutrophil
response ( Williams et al., 2010).
Finally, IL-1 and IL-18 tend to be more harmful cytokines than beneficial in an
acute pneumonia model. Mice deficient in IL-1 and\or IL-18 were protected against a
large challenge dose of PA. However, when a small number of bacteria were used to
infect IL-1 knock out mice, they became more susceptible to chronic infection. Besides
the role of IL-17 in modulation of innate immune responses, it also modulates many
components of the adaptive immune system ( Williams et al., 2010).
Th17 CD4+ cells are formed in the presence of IL-6 and TGF-β cytokines and
are maintained by the presence of IL-23, which is produced by alveolar macrophages.
These cells recruit neutrophils to the site of infection through the actions of IL-17 (
Williams et al., 2010).
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1.7.2 Adaptive Immune Response
The activation of adaptive immune response starts when antigen presenting
dendritic cells migrate to the lymph node where they react with naive T cells to induce
antigen specific proliferation and differentiation of effector T cells (Worbs et

al.,

2017). Multi subunit types of T cells have been identified including CD4, CD8, Th17,
Treg and NKT cells ( Williams et al., 2010). A study done by Worgall et al., concluded
that dendritic cells pulsed with P. aeruginosa elicit an efficient immune response
against pulmonary infection. They Incubated mice bone marrow-derived DC with P.
aeruginosa in vitro, and administered them to syngeneic mice, then the mice were
infected with P. aeruginosa (5 × 104 CFU/mouse) intrapulmonary. 45% of mice
receiving P. aeruginosa-pulsed DC showed sustained survival for more than 14 days.
However, when they pulsed DCs with heat-killed or heat-inactivated bacterium; there
was a protection of CD8-\- mice, but not CD4-\- mice. They concluded that CD4 t cells
are required to induce immunity against pulmonary infection (Worgall et al., 2001).
Another study proved the role of CD4 in eliminating P. aeruginosa from the
lung. Based on a cell transfer experiment, they transferred lymphocytes or CD4 cells
from mesenteric lymph node (MLN) from orally immunized or unimmunized rats with
either killed or activated bacteria to a naïve rat then challenge them with P. aeruginosa.
The study found that the immunized rats only stimulated clearance of bacteria from
airways by the transferred T cell (CD4) from immunized mice (Dunkley et al., 1994).
Furthermore, the C3H/HeN mice strain, known as Th1 responders were more
efficient at eliminating P. aeruginosa from lung than BALB/c mice which are Th2
responders. Protection was accompanied with high levels of interferon (IFN-γ) and low
levels of IL-4 cytokines in the C3HIHeN strain (Moser et al., 1997). Th17 and Th23
have also been implicated in P. aeruginosa response (Williams et al., 2010). Mice
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deficient in either Th17 or Th23 have increased lung tissue damage and mortality
(Curran et al., 2018).
Treg cells play a role in the generation of an immunosuppressive environment.
Treg cells are increased in chronic infection (Williams et al., 2010). Quorum sensing
(QS) systems play an important role in regulating biofilm formation. In a previous study,
QS molecules had complex impacts on the host immune response (Feng et al., 2016).
An experiment on rat models infected with P. aeruginosa found the percentage of
suppressive cytokines (IL-10, TGF-β) and Treg cells were higher in wild type bacteria
compared to QS mutants. This indicates that QS affects the production of some T cell
populations (Treg) and modulation of Tregs in biofilm-associated infections may be
altered by bacterial QS systems. (Feng et al., 2016). NKT cells or CD1d also have a
role in the regulation of P. aeruginosa clearance. These cell populations account for a
small percentage of total T cell population (Williams et al., 2010; Lavoie et al., 2011).
On the other hand, humoral immunity is also required for prolonged protection
against P. aeruginosa. A high level of the aryl hydrocarbon receptor (AHR) is induced
during B cell activation. This has a negative feedback on class switch recombination
and differentiation of B cells to plasma cells that lead to the formation of effector of B
cells and antibody-secreting cells (Vaidyanathan et al., 2017). P. aeruginosa produces
pyocyanin, a phenazine, which binds to the aryl hydrocarbon receptor (AhR), causing
neutrophilic inflammation, which is a part of the host defense response. TLR and AhR
pathways both participate in IL-8 synthesis, known as a neutrophil chemotactic factor.
The AhR played a major role when planktonic P. aeruginosa was grown in a media
favoring phenazine synthesis. However, when P. aeruginosa was grown as a biofilm,
the TLR pathway showed no contribution to biofilm-IL-8 synthesis and AhR was found
to partially contribute to IL-8 synthesis, suggesting the involvement of other unknown
signaling pathway (Roussel et al., 2016).
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A previous study tested the level of IgA in sera and sputa of different groups.
The group infected with P. aeruginosa showed higher levels of IgA titers than the
healthy group and those infected with bacteria other than Pseudomonas. This increase
was due to the presence of monomeric IgA and polymeric IgA in sera and sputa
respectively (Noda et al., 1992). Nevertheless, it is not sufficient to clear P. aeruginosa
infection (Williams et al., 2010).
Several studies have addressed the role of Ig against P. aeruginosa which
could be used to either prevent the infection or clear Pseudomonas bacteria
aeruginosa (Williams et al., 2010; Priebe & Goldberg, 2014). It has been demonstrated
that PcrV+ strains cause a high rate of mortality even in isolates deficient in ExoU and
ExoS cytotoxin proteins. Based on this, PcrV could be a potent therapeutic target
against T3SS Pseudomonas infection (Sato & Frank, 2011; El Solh et al., 2008).
Previous studies have shown the role of polyclonal anti-PcrV antibody in blocking the
translocation of T3SS effector proteins, consequently inhibiting bacterial interaction
with the host cell (Priebe & Goldberg, 2014). An in vitro study showed also blocked
killing of macrophages (Sato et al., 2011). In addition, there was significant protection
in many acute and chronic pneumonia mouse models (Priebe & Goldberg, 2014) and
decreased lung tissue damage and inflammation. Unfortunately, they failed in human
clinical trials (Sawa et al., 1999).
Moreover, an anti-Psa monoclonal antibody (Cam-003) showed effective
protection by minimizing Pseudomonas bacterial growth (Priebe & Goldberg, 2014).
Besides the role of IL-17 in eliminating Pseudomonas during innate immunity, a recent
study illustrated its action in humoral immunity as well (Pan et al., 2016). IL-17 is
produced by T cells during adaptive immune responses. The level of immunoglobin
(IgA, IgG, IgM) was significantly increased in wild type as compared to γδ TCR-/- mice
and improved after IL17-γδ T cell transfusion. Additionally, IL-17 took part in B cell
activation during acute Pseudomonas infection (Pan et al., 2016).
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1.8

Vaccine Design
The termed adjuvants provide the “help” (from adjuvare, to help) needed to

enhance and boost immunity to vaccines and antigens (Coffman et al., 2010). In the
era of the development of novel vaccines, adjuvants have been used successfully to
boost the host immune response to poorly immunogenic purified antigens and subunit
vaccines (Di Pasquale et al., 2015; Coffman et al., 2010). Additionally, adjuvants could
improve immune responses in those who respond poorly to vaccination (Di Pasquale
et al., 2015). In 1932, Alexander Glenny exploited the effects of immune response on
aluminum salt at a time when aluminum was the only licensed adjuvant. Aluminum acts
by elevating antibody production therapy; it is an efficient adjuvant used in human
vaccines against pathogens which are killed mainly by antibodies (Di Pasquale et al.,
2015). However, aluminum fails to eliminate intracellular bacteria (Coffman et al.,
2010). In the mid- 1990s, a virosome adjuvant system was used in the Hepatitis B
vaccine. This triggered the initiation of adaptive T cell responses and B cell activation.
Scientists have also designed a combination of adjuvants, known as an adjuvant
system, to enhance T cell immune response (Di Pasquale et al., 2015).
In this study, we aim to exploit the Tobacco Mosaic Virus (TMV) based delivery
system due to its ability to serve as an adjuvant and deliver multiple protective
Pseudomonas antigens into a novel vaccine formulation (Banik et al., 2015; Arnaboldi
et al., 2016; Kernan et al., 2017). TMV has a simple functional structure, a 6.4 kb
positive-strand RNA core surrounded by 2130 copies of an identical coated protein to
prevent RNA degradation by enzymes (Stubbs, 1999; Simmons & Blout, 1960;
McCormick & Palmer, 2008). Viral RNA is infectious by itself to a wide range of plants
and tobacco; however, it is not infectious for humans or animals (McCormick & Palmer,
2008). Recently, TMV has appeared in vaccine development due to its ability to
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function as nanoparticles (McCormick & Palmer, 2008; Kernan et al., 2017; McCormick
& Palmer, 2008).
Recombinant TMV was developed in the lab of Dr. Alison McCormick and
contains a surface exposed, reactive lysine residue incorporated into the coat protein
allowing for the chemical conjugation of antigens to the viral surface. Besides its ability
to deliver proteins via conjugation (Kemnade et al., 2014), TMV has many
characteristics that potentiate vaccine formulation. First is the ability to enhance
antigen specific T cell immunity (Kemnade et al., 2014) and generate vaccine-specific
antibodies (Banik et al., 2015; Arnaboldi et al., 2016) due to its nonfunctional RNA and
repetitive antigens on its surface that mimic an effective virus surface (McCormick &
Palmer, 2008). Second, no evidence has shown that TMV induces neutralizing
antibodies that block its function as an antigen delivery system (Kemnade et al., 2014).
TMV is very stable at different temperatures, which allows it to be used repetitively for
boosting (McCormick & Palmer, 2008).
Several studies have used TMV as a carrier to deliver multi-subunit vaccines
(Banik et al., 2015). In tularemia studies, the administration of subunit vaccines
conjugated to TMV showed significant enhancement of humoral immune response
compared to the proteins alone. This, induced a high level of antibody production
therapy that protected mice from respiratory infections (Banik et al., 2015). Our group
utilized TMV to intranasally deliver a subunit vaccine against Yersinia pestis (the
causative agent of plague). Administration of a subunit vaccine for Y. pestis (F1 and
LcrV) intranasally induced a significant production of antibody (IgG) and protected mice
from lethal challenge with pneumonic plague (Arnaboldi et al., 2016). Moreover, an
experiment in a murine model, used virus-like particles (TMV) containing the hybridcoating protein 13 amino acid sequence of the murine zona pellucida ZP3 protein.
Immunizing mice with this hybrid protein resulted in the production of specific
antibodies, ZP3 peptides (Fitchen et al., 1995) and breaking B cell tolerance since B
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cells reactive to antigens have been shown to be tolerized (McCormick & Palmer,
2008). Ultimately, TMV could be a potential adjuvant for novel vaccines to induce
complete protection against pulmonary infection (Arnaboldi et al., 2016) and develop
subunit vaccines for other bacteria in the future (Banik et al., 2015).
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2.0 Hypothesis and Specific Aims:
2.1 Hypothesis:
Pseudomonas aeruginosa (PA) is an opportunistic human pathogen that
causes a range of severe and fatal infections, especially in critically ill and
immunocompromised patients. Cystic Fibrosis patients, for example, are at a high risk
of P. aeruginosa. P. aeruginosa is the most common Gram-negative bacterium that
causes nosocomial pneumonia (chronic or acute) in the United States. In addition, it is
a ubiquitous pathogen found throughout the atmosphere that can colonize a wide range
of organisms (Lyczak et al., 2002; Tümmler & Klockgether, 2017; Gellatly & Hancock,
2013).
P. aeruginosa has been studied intensively. Several candidate antigens were
identified for use in subunit vaccines: LPS, flagella, alginate, and a variety of surface
proteins and virulence factors. While previous studies made many attempts to design
vaccines, the lack of an adequate delivery system has been a limiting factor in the
development of a safe and effective PA vaccine (Priebe & Goldberg, 2014). As P.
aeruginosa is resistant to multiple antibiotics (a number that is constantly
growing)(Curran et al., 2018), the goal of this study is to explore a potential vaccine
using a tobacco mosaic virus- based delivery platform that provides optimal protection
against P. aeruginosa respiratory infections and generates protective immune
responses. Ultimately, the aim is to find alternatives to prevent and/or treat P.
aeruginosa infection.
In this study, we hypothesized that conjugating the tobacco mosaic virus
(TMV) chemically to Pseudomonas antigens protects against the development of
pneumonia respiratory infections. Two specific aims were designed for this study.
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2.2 Specific Aim 1: Produce a functional TMV-conjugate vaccine for P.
aeruginosa
PcrV is highly conserved among all Pseudomonas strains and is the tip protein
of type 3 secretion system. We cloned and expressed recombinant PcrV protein. The
protein was conjugated to TMV to develop a vaccine that is ready for mice testing. In
addition, we cloned and expressed two P. aeruginosa proteins (OprI and OprF) that will
be conjugated to TMV and tested as a vaccine in mice. Unfortunately, the extended
troubleshooting prevented the study of the efficacy of OprI and OprF.

2.3 Specific Aim 2: Evaluate the effectiveness of TMV-PcrV in a model of acute
pneumonia.
The hypothesis was tested using intranasal administration to immunize mice
with PcrV-TMV vaccine. Antibody production was assessed after each booster as well
as morbidity and mortality in mouse models of acute (nonmucoid) PA pneumonia. In
addition, we assessed the effectiveness of TMV-PcrV with di-c-GMP adjuvant for
enhancing a systemic immune response.
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3.0 Materials and methods:
In Vitro Assay:
3.1 Bacterial Strains:
P. aeruginosa Boston 41510 was used in all experiments for this study. It was
obtained from the American Type Tissue Culture Collection (ATCC). E. coli TOP10 and
E. coli BL21(DE3) (Invitrogen, Grand Island, NY) were used for cloning and expression
of recombinant PcrV proteins, respectively. E. coli BL21 PlySE (DE3) (Invitrogen) was
used for the expression of recombinant OprI and OprF proteins.

3.2 Expression and Purification of Recombinant Proteins:
3.2.1 Cloning, Expression and Purification of Recombinant
PcrV Protein of P. aeruginosa:
P. aeruginosa was cultivated in Trypticase Soy Broth (TSB) overnight at 37°C
in a shaking incubator (225 rpm). After culture, P. aeruginosa bacterial DNA was
isolated using Wizard Plus SV minipreps DNA purification system according to the
manufacturer’s instructions (Promega). DNA concentration was quantitated using a
Denovix microvolume spectrophotometer. Bacterial DNA was stored at -80°C for
further use. Bacterial DNA was isolated using Wizard Plus SV minipreps total DNA
purification system according to the manufacturer’s instructions (Promega). PcrV gene
was

amplified

using

forward

(F_pcvR_NdeI):

CTGAGGAATCATGCATATGGAAGTCAGAAACCTT and reverse (R_pcrvR_EcoRI):
CAGTTGCATGCTGAATTCTAGATCGCGCTGAGAATGTC primers.
PCR reaction was performed using Thermo Fisher Master Mix and gradient PCR
where the PCR Conditions for PcrV were 36 cycles of 95°C 5 min, 95°C 30sec, gradient
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30sec, 72°C 1:15min, 72°C 10min. PCR products were checked on a 1% agarose gel.
pET28a vector and PcrV PCR product were digested by NdeI and EcoRI at 37°C
overnight. All digested DNA were cut and purified from a 0.7% agarose gel, using the
Wizard SV Gel and PCR clean-up system according to manufacturer’s instructions
(Promega) and ligated overnight at 4°C. The ligated product was transformed into E.
coli BL21(DE3) (Invitrogen) in LB agar plates containing kanamycin (50 μg/ml)
overnight at 37°C. Sequence verification was confirmed using Sanger sequencing.
Bacteria transformant was grown and bacteria was grown on LB broth containing
kanamycin (50 μg/ml) at 37 °C to an OD600 of 0.4. Expression was induced by the
addition of 0.75 mM of Isopropyl β- d-1-thiogalactopyranoside (IPTG) and grown in
shaker incubation at 37°C for an additional 5 hours. Cells were pelleted at 5000 rpm
for 10 min. Pellets were stored at -20°C until protein purification. The protein was
purified at 4°C using a nickel nitrilotriacetic acid (Ni-NTA) column chromatography (2ml bed volume), equilibrated with 3 volumes of binding buffer containing 20 mM
imidazole (pH 7.5). The column was washed with 2 volumes of the same buffer 2x,
followed by the second wash with 3 volumes of washing buffer 5x containing 40 mM
imidazole (pH 7.5). Bound protein was eluted in 50 mM Tris-HCl (pH 7.5)-150 mM NaCl
with either 250 mM or 500 mM imidazole (pH 4). The purity of the protein was
confirmed by SDS-PAGE and Western blot analysis. Protein concentration was
determined by RC DCTM Protein Assay (Bio-Rad), and protein was stored at -20°C.
PcrV cloning and purification were performed by Christina Toumanios in the lab.
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3.2.2 Expression and Purification of Recombinant OprI and
OprF Protein of P. aeruginosa:
The OprI and OprF genes were obtained from Invitrogen, (Grand Island, NY) in
a pET100/D-Topo expression vector. The plasmids were transformed into E. coli
PlySE(DE3) (Invitrogen). Single colony transformants were grown in LB containing
carbenicillin (100 μg/ml) and chloramphenicol (34 μg/ml) overnight at 37°C in a shaking
incubator at 225RPM, and plasmids were purified using the PureYieldTM Plasmid
Midiprep System according to the manufacturer’s instructions (Promega, Madison, WI,
USA). The sequences were verified by Sanger sequencing (Genewiz, South Plainfield,
NJ). Bacterial glycerol stocks in 25% glycerol were generated for each sequence
confirmed colony and stored at -80 °C for further use. Bacteria transformants were
grown in LB broth containing carbenicillin (100 μg/ml) and chloramphenicol (34 μg/ml)
at 37°C in a shaking incubator at 225RPM overnight and were used to streak LB agar
plates (containing the same antibiotics). Single colonies were used to inoculate 10ml of
LB media and bacteria was grown overnight as described above. The next morning a
larger culture was inoculated with a 1:20 dilution of the overnight culture and grown until
it reached an OD600 of 0.4. Expression was induced by the addition of 0.75 mM of IPTG
and bacteria grown in a shaker incubator (225RPM) at 37°C for an additional 3 hours.
Cells were pelleted by centrifugation at 5000 rpm for 10 min and then store at -20°C.
Protein was purified using nickel-NTA column chromatography (Sigma, St Louis, MO)
according to the manufacturer’s instructions. All buffers contained 8M Urea, 50 mM
sodium phosphate, and 300 mM NaCl. The column (2-ml bed volume) was equilibrated
with 3 volumes of binding buffer containing 8M Urea, 5mM Imidazole, 50 mM sodium
phosphate, and 300 mM NaCl (pH 8). The lysis buffer contains 25% Triton X-100,
25% Tween 20, protease tablet, 125µg of lysosome, DNase I RNase-free, and RNase
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A. The column was washed with 2 volumes of the same buffer 2x, followed by the second
wash with 2 volumes of washing buffer 5x containing 8M Urea, 20Mm Imidazole, 150
mM sodium phosphate, and 300 mM NaCl (pH 7). Bound protein was eluted in 50 mM
Tris-HCl (pH 7.5)-150 mM NaCl with 250 mM imidazole, and 8M Urea (pH 4). The purity
of the protein was confirmed by SDS-PAGE and Western blot analysis. Protein
concentration was determined by RC-DC Protein Assay (Bio-Rad), and stored at -20°C.

3.2.3 Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE):
Two 10% and 15% SDS-PAGE gels were prepared. Proteins samples were
mixed with 6x of loading dye, then heated at 95°C for 5 minutes to denature proteins.
10µl of protein samples and 2µl of Page Ruler Pre-Stained Protein Ladder (Thermo
Scientific) were loaded into wells of gels. The samples were run at 120 volts for around
2 hours or until the dye front reached the bottom of gels. The two gels were removed
and one stained with the Coomassie blue dye and the second used for western blot
analysis.

3.2.4 Western Blot Analysis:
The proteins on the gel were transferred onto polyvinylidene difluoride
membranes nitrocellulose membrane (PVDF) using a Semi-Dry transfer apparatus (BioRad) according to the manufacturer’s instruction. After transfer, the membrane was
washed three times with 1x of Tris-Buffered Saline and Tween 20 (TBST) buffer
containing 0.05%TWEEN 20 for 3 minutes. Then, the membrane was blocked with
1%BSA in 1x TBST of blocking buffer for 1 hour at room temperature with gentle
shaking. This was followed by incubation of the membrane for 2 hours at room
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temperature with Monoclonal-PolyHistidine as primary antibody obtained from (Sigma,
St. Louis, MO) and diluted in blocking buffer (1:3000). The primary antibody was
removed by washing membrane with 1x TBST buffer containing 0.05%TWEEN 20 3x
for 5 minutes each at room temperature. After washing, the membrane was incubated
with secondary antibody Alkaline Phosphate Affinity-Purified Goat Anti-Mouse IgG
(H+L)(Jackson ImmunoResearch) (1:5000) dilution for 1 hour with gentle shaking at
room temperature. After the incubation, the membrane was washed again with 1x TBST
buffer containing 0.05%TWEEN 20 three times for 5 minutes, and the fourth washing
with water for 2 minutes at room temperature with gentle shaking. Antibody binding was
detected using Alkaline-Phosphatase substrate (NBT/BCIP) for up to 15 minutes,
resulting in the appearance of a dark-colored band.

3.3 Generation and Purification of TMV:
TMV purification and conjugations were done by our collaborator Alison
McCormick at Touro University, California.

3.3.1 Conjugation of P. aeruginosa Proteins to TMV:
Conjugation of P. aeruginosa proteins to TMV was performed by Dr. Alison
McCormick at Touro University to design Pseudomonas proteins onto the TMV surface.
5mg of PcrV was conjugated to 5mg of single TMV virion. Successful conjugation of
recombinant protein of P. aeruginosa to TMV virion was determined by SDS-PAGE.
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In Vivo Assay:
3.4 Immunogenicity and Protective Efficacy of TMV Conjugated
Vaccine:
3.4.1 Mice
C57BL/6 mice were purchase from Jackson Laboratories (Bar Harbor, ME).
Six-week-old male and female mice were used in all experiments. Mice were
maintained by the Department of Comparative Medicine of New York Medical College
in specific-pathogen-free environment. All animal experiments were performed
according to the New York Medical College Animal Care and Use Committee
guidelines using approved protocols.

3.4.2 Vaccine Formulation:
Two different vaccine formulations were used. First, PcrV protein was
conjugated with single TMV separately, which is designed as TMV- conjugated
vaccine. The second formulation was TMV-PcrV vaccine mixed with di-c-GMP
adjuvant (Figure 1).

3.4.3 Immunization Schedule:
Schedule I: C57BL/6 mice were immunized intranasally (i.n.) with 20µg of TMV-PcrV
vaccine and 10µg of rPcrV protein in PBS. TMV-PcrV consists of 10µg of TMV and 10µg
of rPcrV, thus control mice receive 10µg of rPcrV to equivocate the amount of antigen
used. Mice were given doses on day 0, 14, and 28. On day 0 the mice were immunized
i.n. with 50µl volume of the vaccine in one nostril. For booster vaccinations, days 14 and
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28 after the first immunization, mice were immunized i.n with 40µl volume of the vaccine
formulation in one nostril. A group of mice that received no vaccine was used as a
control. All mice were bled on days 21 and 35 and sera were analyzed to determine total
antibody response. All mice were challenged with P. aeruginosa Boston 41510 on day
42 after primary immunization (Figure 2A).
Schedule II: C57BL/6 mice were immunized intranasally (i.n.) on days 0, 21, and 35.
They received 20µg of TMV-PcrV vaccine mixed with 2µg of di-c-GMP adjuvant and
20µg of rPcrV protein mixed with 2µg of di-c-GMP adjuvant in the volume of 40µl of the
vaccine formulation in one nostril. A group of mice that received no vaccine were used
as a control. All mice were bled on days 14, 28 and 42 and blood sera were collected
from immunized and control mice to determine total and isotype specific antibody
response. All mice were challenged with P. aeruginosa Boston 41510 on day 49 after
primary immunization (Figure 2B).
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Figure 1: Vaccine formulation. Two different formulations were used. First, PcrV
protein was conjugated with single TMV separately, which is designed as TMVconjugated vaccine. The second is TMV-PcrV vaccine mixed with di-c-GMP adjuvant.
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Figure 2: Time points of the immunization schedules. A) C57BL/6 mice were
immunized intranasally with 20µg of TMV-PcrV vaccine or 10µg of rPcrV protein and
booster vaccinations were administrated i.n. using similar doses on days 14 and 28.
B) C57BL/6 mice were immunized intranasally with the same formula included 2µg of
di-c-GMP adjuvant. Two boosters were administered with a similar dose on days 21
and 35.
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3.4.4 Immunogenicity of TMV Vaccine:
For the detection of P. aeruginosa specific antibody induced in vaccinated
mice, ELISA was performed using rPcrV protein to determine total anti-PcrV specific
antibody levels. Blood was collected from mice immunized with TMV-PcrV, rPcrV, and
control mice, and centrifuged at 5000 rpm at room temperature for 15 minutes to collect
the sera. Sera were stored at -20°C until analysis. Ninety-six wells microtiter plates
(Thermofisher- Scientific) were coated with 3µg/ml of rPcrV diluted in coating buffer (0.1
M of Sodium Carbonate, pH9.4) for 1 hour at room temperature. Plates were washed
three times with washing buffer (1xPBS with 0.05% TWEEN20). After washing, blocking
was performed by adding 250µl/well of blocking buffer (1%BSA in PBS) then the plates
were incubated at room temperature for 1 hour. The plates were washed again to
remove the blocking buffer. The sera were diluted in blocking buffer (1%BSA in PBS),
and added to each well then the plates incubated at room temperature for 1 hour. Plates
were washed three times with washing buffer (1xPBS with 0.05% TWEEN20). Goat AntiMouse Ig (H+L)-HRP (Southern Biotech Birmingham, AL) was diluted at 1:5000 in
blocking buffer (1%BSA in PBS) and, added to each well and plates incubated for 1 hour
at room temperature. Plates were washed again three times with washing buffer (1xPBS
with 0.05% TWEEN20). TMB substrate (KPLSeraCare) was added to plates 50µl/well
volume and plates were incubated in the dark for 30 minutes at room temperature.
Finally, 50µl/well of 2N sulfuric acid was added as stop solution, and the color density
was read at 450nm and 570nm. The data were plotted as absorbance vs. reciprocal
serum dilution, and the 50% maximal binding titers were interpolated from the plotted
curves using Prism 7.0. Interpolations were only performed, from curves that had at a
maximal binding absorbance of greater than OD450-570 of 0.200.
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3.4.5 Mice Challenge Studies:
P. aeruginosa Boston 41510 was cultivated in Trypticase Soy Broth (TSB)
overnight at 37°C in a shaking incubator (225 rpm). The following morning, this culture
was used to seed another broth culture (1:20 diluting) which was grown until the OD600
was between 0.6 and 0.9. The culture medium was removed by washing 3x with normal
saline and centrifugation at 5000 rpm for 10 minutes at room temperature. The culture
was resuspended in normal saline to an OD600 of ~1.25. This corresponds to ~2 x 10 9
CFU/ml. The lethal dose 50 of P. aeruginosa Boston 41510 was previously determined
to be 2x107-6 CFU in an acute pneumonia model. Groups of immunized and control mice
received 1x108 or 1x107 CFU for the challenge. 2-3 doses are commonly used for
challenge studies of Pseudomonas. Mice were anesthetized by intramuscular injection
with a cocktail of ketamine/xylazine (100mg/10mg/kg). All mice groups (TMV, rPcrV, and
control) were split into two groups for the bacterial challenge. The first group was
challenged i.n. with 1x10 8 CFU in one nostril (50µl) and the second group was
challenged i.n. with 1x10 7 CFU in one nostril with (50µl) volume. Challenges were
performed in a BLS2 biosafety cabinet. The number of bacteria inoculated into mice on
the day of the challenge was confirmed by plating serial dilutions on TSB agar plates
incubated for 24 hours at 37°C.

3.4.5.1 Post-Challenge Studies:
Challenged mice were monitored daily for morbidity (hunched posture, loss of
activity, weight loss) and mortality for four days post-infection. A previous study has
demonstrated that mice surviving greater than 4 days do not succumb to infection. Mice
were weighed every day until they regained their pre-infection weight. Mice that lost
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more than 20 % of their original body weight were euthanized. Experiments continued
until all mice recovered and regained their original weight before infection.

3.4.6 Statistical Analysis:
Antibody levels of immunized mice are presented as mean absorbance (450570nm) ± Standard Deviation (SD) or mean ± Standard Error of Mean (SEM). Antibody
titers were compared between TMV-PcrV and rPcrV by Student’s T-test. Survival data
were presented by Kaplan-Meier Survival curves, and were compared by Mantel-Cox
Test. Data were statistically analyzed using GraphPad Prism 7.0 (GraphPad Software,
Inc, USA).
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4.0 Results:
4.1 Expression and Purification of Recombinant PcrV, OprI and
OprF Proteins of P. aeruginosa:
The P. aeruginosa PcrV, OprI, and OprF proteins were expressed in bacterial
expression system E. coli BL21(DE3), E. coli PlySE(DE3), and E. coli PlySE(DE3),
respectively, tagged with N-terminal 6X-His protein then purified by nickel nitrilotriacetic
acid (Ni-NTA) column chromatography. The purity of proteins was confirmed by SDSPAGE and Western blot analysis using Monoclonal-PolyHistidine as the primary
antibody. Bands of 37kDa, 12kDa, and 42kDa confirmed the identity of PcrV, OprI and
OprF proteins, respectively (Figure3).
OprI and OprF expression and purification required substantial troubleshooting.
The optimizing conditions for OprI and OprF protein expression and purification were
totally different from PcrV protein. In the first attempt, we followed the same growth
conditions as we did with PcrV. We used E. coli BL21(DE3) to express our proteins,
100µg of ampicillin antibiotic, 0.75mM of IPTG with 5 hours induction time.
Unfortunately, no protein bands were seen on the polyacrylamide gel; however, a very
low expression was detected by western blot using Monoclonal-PolyHistidine. In the
second attempt, we replaced the 100µg of ampicillin with 100µg of carbenicillin, which
is more stable than ampicillin and helps to increase the expression levels by preventing
loss of the pET TOPO® plasmid. A high expression level was detected on western blot
only. Next, we purified our proteins using the same PcrV protocol, where it has done at
4°C. After protein purification, no bands were seen on the polyacrylamide gel. A band
was observed only on western blot using Monoclonal-PolyHistidine. We discovered that
we lost substantial protein during the wash steps in the protocol. At this point, we figured
out the problem was not only associated with protein expression, but also with the
purification method. We decided to perform cell lysis for inclusion body as well to see if
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our proteins were there. As we expected, most of our proteins were in the inclusion body.
This result showed us that the purification methods for OprI and OprF are different. We
also decided to use urea buffer. In the final attempt, we changed the IPTG stimulation
time as well as the bacterial expression system. We expressed our proteins in E. coli
PlySE(DE3) and the induction time was reduced from 5 hours to 3 hours with the same
IPTG concentration and 100µg of carbenicillin. Finally, clear bands were observed on
both the polyacrylamide gel and western blot analysis. For this attempt, we purified our
proteins using a buffer containing 8M of urea, 50 mM sodium phosphate, and 300 mM
NaCl.
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PcrV

OprF

OprI

Figure 3: Expression and purification of recombinant PcrV, OprI, OprF proteins
of P. aeruginosa. Purification of recombinant PcrV OprI, OprF proteins was confirmed
by SDS-PAGE and Western blot analysis using anti-PolyHistidine Monoclonal
antibodies.
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4.2 Immunization with TMV-PcrV Vaccine Generates a Strong
Antibody Response:
We examined the level of total antibodies generated in response to TMV-PcrV.
We determined antibody response in mice that were vaccinated with 20µg of vaccine
conjugate (TMV-PcrV) or 10µg of unconjugated rPcrV and that received two boosters
on days 14 and 28. Mice were bled on day 21 and day 35 post-primary immunization
and total antibody response was detected using an ELISA assay coated with the rPcrV
protein.
A stronger antibody response was detected for the TMV conjugate vaccine
compared to the recombinant PcrV protein and unvaccinated group (Figure 4). The
level of total antibodies observed on day 35 for the TMV-PcrV vaccine were much
higher than those observed on day 21 (Figure 4). The antibody response was still
detectable at a dilution of 25,600 in TMV-PcrV vaccine on both days 21 (Figure 4.A)
and 35 (Figure 4.B).
Vaccine-specific antibody titers were elevated in the mice that received TMVconjugated vaccine protein compared to the recombinant protein alone (Figure 5.A).
However, the average level of vaccine-specific antibody titers with TMV-conjugated
vaccine on day 21 was higher than the mean of antibody titers on day 35 (Figure 5.B).
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Figure 4: Immunized mice with TMV-PcrV vaccine generate a strong antibody
response. C57BL/6 mice were immunized i.n. with TMV-PcrV vaccine (n=10/group).
On days 21 (A) and 35 (B) post-primary immunization, anesthetized mice were bled
retro-orbitally to obtain serum. P. aeruginosa specific total antibodies levels in serum
samples were determined using an ELISA plates coated with P. aeruginosa rPcrV
protein. The data are presented as Mean ± S.D.
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Figure 5: Immunized mice with TMV-PcrV vaccine generate a strong antibody
response. 50% maximum binding titers were calculated for total PcrV specific
antibodies levels in mice vaccinated and boosted with TMV-PcrV (n = 10) and
recombinant PcrV (n = 10) on days 21 (A) and 35 (B). P-value= 0.1570 was
determined by Paired test.
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4.3 Immunization with TMV-PcrV including di-c-GMP Generates
Stronger Antibody Response than rPcrV+ di-c-GMP Alone:
We next examined the total antibody response generated in mice where 2ug of
the di-cyclic-GMP adjuvant were included in the vaccine formulation. The second
vaccine schedule included 2 boosters on days 21 and 35 post-primary immunization
and mice were bled retro-orbitally on days 14, 28, and 42. As we expected the total Ig
response observed on days 28 and 42 were significantly higher than those observed
with mice that were vaccinated with the rPcrV vaccine only (Figure 6).
The total level of antibody responses observed in the most diluted sera (51200)
with TMV-PcrV+ di-c-GMP was notably higher than the rPcrV+ di-c-GMP vaccine after
the two boosters (Figure 6.B and 6.C). Furthermore, many mice vaccinated with the
TMV vaccine formulation, including di-c-GMP generated a higher level of PcrV-specific
antibody than immunized mice with the rPcrV+ di-c-GMP (Figure 6.B and 6.C).
Vaccine-specific antibody titers were elevated in the mice that received TMVPcrV+ di-c-GMP compared to the rPcrV protein+ di-c-GMP (Figure 7.B and 7.C).
Interestingly, the average level of total PcrV specific Ig titers with the TMV-conjugated
vaccine that included the di-c-GMP adjuvant was elevated significantly compared to the
mean of antibody titers after two boosters (P-value <0.0001) (Figure 7.B and 7.C).
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Figure 6: Immunization with TMV-PcrV including di-c-GMP generates stronger
antibody response than rPcrV+ di-c-GMP alone. C57BL/6 mice were immunized
i.n. with TMV-PcrV vaccine (n=20/group). On days 14 (A) 28 (B) and 42 (C) postprimary immunization, anesthetized mice were bled by retro-orbitally to obtain serum.
P. aeruginosa specific total antibodies levels in serum samples were determined using
an ELISA plates coated with P. aeruginosa rPcrV protein. The data are presented as
Mean ± S.D.
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Figure 7: Immunization with TMV-PcrV including di-c-GMP generates stronger
antibody response than rPcrV+ di-c-GMP alone. 50% maximum binding titers were
calculated for total PcrV specific antibodies levels in mice vaccinated and boosted with
TMV-PcrV (n = 20) and recombinant PcrV (n = 20) on days 14 (A) 28 (B) and 42 (C).
Asterisk (*) illustrates the significance. P-value <0.0001 was determined by Paired t
test.
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4.4 Protective Efficacy of the TMV-Conjugate Vaccine against
Acute Pneumonia:
We tested the efficiency of the TMV-conjugate vaccine by performing the two
schedules described in the methods section. Mice were challenged intranasally with
two lethal doses of P. aeruginosa 1x108 and 1x107 seven days after the second
booster. Infected mice were then monitored for morbidity and mortality 2x per day until
they regained pre-challenge weight.
In the first vaccine experiment (schedule I), 100% of the control mice that were
challenged with 1x108 CFU bacteria and received no vaccine succumbed to infection
by day 1. All mice immunized with TMV-PcrV that received the same dose died by day
2, demonstrating a right shift in MTD (Figure 8). In the second group, challenged with
1x107 CFU bacteria, all unvaccinated mice succumbed to infection by Day 2.5 (the
afternoon of Day 2), while 80% of mice vaccinated with TMV-PcrV survived the
infection (Figure 8).
In the second vaccine experiment (schedule II), 100% of unvaccinated mice
challenged with 1x108 CFU bacteria succumbed to infection by the morning of day 1.
50% of rPcrV + di-c-GMP receiving the same dose died by the afternoon of day 1 postinfection (day 1.5) and the rest succumbed to infection by the afternoon of day 2 postinfection (day 2.5). A similar response was observed in the TMV+ di-c-GMP group;
60% of the mice died by the afternoon of the first-day post-challenge (day 1.5), while
the remaining 40% succumbed to infection by the afternoon of the second day postchallenged (day 2.5) (Figure 9). In the group that received 1x10 7 CFU bacteria, all
unvaccinated mice succumbed by the afternoon of day 2 post-infection (day 2.5).
Conversely, 60% of TMV-PcrV+ di-c-GMP mice and 50% of rPcrV+ di-c-GMP survived
the infection. The death occurred at a more rapid rate in mice vaccinated with rPcrV
compared to mice vaccinated with TMV-PcrV (Figure 9).
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Figure 8: Protective efficacy of TMV-vaccine against an acute pneumonia model.
Survival of mice vaccinated (n=10) i.n. with TMV-PcrV. Immunized mice (n=5/group)
were challenged i.n. with 1x108 or 1x107 CFUs of P. aeruginosa on day 42 post-primary
immunization. Mice (n=10) received no vaccine served as controls. Challenged mice
were monitored for morbidity and mortality for four days post-challenging. P-value=
0.0003 was determined by Log-rank (Mantel-Cox) test.
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Figure 9: Protective efficacy of TMV-vaccine against an acute pneumonia model.
Survival of mice vaccinated (n=20) i.n. with TMV-PcrV+ di-c-GMP. Immunized mice
(n=10/group) were challenged i.n. with 1x10 8 or 1x107 CFUs of P. aeruginosa on day
49 post-primary immunization. Mice (n=20) received no vaccine served as controls.
Challenged mice were monitored for morbidity and mortality for seven days postchallenging. P value <0.0001 was determined by Log-rank (Mantel-Cox) test.
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5. Discussion:
Pseudomonas aeruginosa is an opportunistic pathogen. It is responsible for a
wide range of diseases, mostly in hospitalized, immunocompromised patients, patients
with burn wounds, and patients with cystic fibrosis (Williams et al., 2010). The
increasing antibiotic resistance of P. aeruginosa creates an urgent need for vaccines,
yet there is no FDA-approved P. aeruginosa vaccine and recent promising candidates
have failed in large clinical trials.
Research on Pseudomonas has been focused mainly on developing an LPSbased vaccine, a live attenuated vaccine, a killed whole-cell vaccine, and subunit
vaccines. However, some vaccines were limited by toxicity, inefficient protection, and
lack of appropriate delivery system, which halted progress (Priebe & Goldberg, 2014).
Once developed, the pulmonary disease is difficult to treat; therefore, effective
prophylaxis against Pseudomonas aeruginosa would be highly significant (Kalil et al.,
2016; Gellatly & Hancock, 2013). There are many trials to develop antibody-based
therapy against Pseudomonas infections, but unfortunately, none of these has been
approved by U.S Food and Drug Administration. Most fail in phase 2 or 3 clinical trial
development (Priebe & Goldberg, 2014).
Recently, developing the subunit vaccines using the adenoviral vector and
keyhole limpet hemocyanin (KLH) delivery platform showed great promise in animal
models and significant protection against acute pneumonia since adenoviral vectors
display an OprF peptide that has both B and T cell epitope (Priebe & Goldberg, 2014).
Other proteins including outer membrane proteins (OprF and OprI), were
investigated as a subunit vaccine that showed a well-tolerated reaction in a human trial
as well. However, despite different subunit components providing good protection, they
either failed or protected only against 50% of lethal doses of P. aeruginosa (Priebe &
Goldberg, 2014). A reasonable explanation of the limited protection of these subunit
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vaccines, even though they are potently immunogenic, is the lack of an adequate
delivery platform or adjuvant that can deliver antigen in a consistent way.
The purpose of this study was to explore and generate proof of concept data
for a potential vaccine using a TMV delivery platform that offers adequate protection
against respiratory P. aeruginosa infections. TMV is a potent antigen carrier that has
been found to provide a robust humoral response since it has repetitive antigens that
mimic the virus's surface. This is essential in generating a strong antibody response
(McCormick & Palmer, 2008). In addition, TMV's nonfunctional RNA only in animals is
significant for inducing Th1 cellular immunity (McCormick & Palmer, 2008; Kemnade
et al., 2014).
In our study, we used the purified proteins of P. aeruginosa for TMV conjugation
studies and tested the efficiency of TMV Pseudomonas protein conjugates to prove
the concept and ability of TMV as a carrier for Pseudomonas antigens. For our ultimate
study, three genes of P. aeruginosa encoding for PcrV, OprI, and OprF were cloned in
E. coli expression vector pET28a, Pet100/D-TOPO, and Pet100/D-TOPO, respectively
and expressed in E. coli BL21(DE3), E. coli PlySE(DE3), and E. coli PlySE(DE3)
competent cells, respectively. They were then purified using metal affinity
chromatography.
These three genes were selected based in part on a previous study done in our
lab with Y. pestis LcrV, which is an analogue of PcrV, that showed a high level of
protection (Arnaboldi et al., 2016). Similarly, these outer membrane proteins were used
in other studies as subunit vaccines and showed high levels of stimulating IgG
responses as well as inducing IFN-γ CD4 and CD8 responses (Priebe & Goldberg,
2014; Yang et al., 2017). PcrV was chemically conjugated to the TMV surface using
(EDC) and (NHS) protocol by Dr. Alison McCormick and her lab members at Touro
University in California. Our initial intention for this thesis was to conjugate and test
OprF and OprI as well. However, extensive troubleshooting was required to produce
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these two proteins. While both proteins were ultimately produced and purified in
sufficient quantities, we were unable to have them conjugated in time for in vivo
studies.
Two vaccine formulations were used in this study consisting of the vaccine
conjugate (TMV-PcrV) or unconjugated protein (rPcrV) and di-cyclic-GMP adjuvant
were included with the vaccine group.
Anti-PcrV antibody was generated in both the presence and absence of TMV
but was enhanced by chemical conjugation of PcrV to TMV. In our LcrV studies,
chemical conjugation between the protein antigen and TMV has been shown to be
critical for enhancing antibody production. This indicates that PcrV is strongly
immunogenic and that antigenicity is enhanced by TMV.
Additionally, in the first experiment with the PcrV-TMV, an 80% of survival rate
was observed after mice received 3 doses of vaccine on days 0, 14 and 28 then were
challenged with 1x107 CFU of Pseudomonas bacteria (Figure 8). Recombinant protein
alone was absent from this challenge experiment because the group was accidentally
euthanized by Dr. Arnaboldi during a scheduled retro-orbital bleed. This result proves
the efficiency of TMV as a potent delivery platform of Pseudomonas antigens and
stimulates a robust protective immune response.
Furthermore, when we compared the humoral immune response of two
immunization schedules, di-c-GMP adjuvant appeared to greatly enhance the antiPcrV antibody response, when comparing the magnitude of the antibody response in
TMV-PcrV or rPcrV mice to that of unvaccinated mice (Figure 4 and 6). Collectively,
these results indicate that a TMV-PcrV+ di-c-GMP adjuvant vaccine is an efficient
vaccine formulation that can generate a potent humoral immune response. Despite
this, vaccine-mediated protection was not enhanced by the addition of a di-cyclic-GMP
adjuvant.
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In the second experiment (schedule II), where di-c-GMP was included with the
vaccine formulation, more than 60% of survival rate was observed after TMV mice
received 3 doses of vaccine on days 0, 21 and 35 then were challenged with 1x10 7
CFU of Pseudomonas bacteria. In contrast, 50% of mice vaccinated with rPcrV
survived (Figure9). Compared to the survival rate in the first experiment, these results
indicate that the inclusion of di-c-GMP in the vaccine formulation can enhance antibody
production for both TMV and rPcrV groups (Figure6), but enhanced antibody
production does not translate to enhanced survival.
The inability of TMV-PcrV to completely protect against lethal challenge with P.
aeruginosa suggests that additional antigens are needed for full protection. In addition,
it is not clear that all strains of Pseudomonas will utilize the same spectrum of virulence
factors providing further support for the inclusion of additional vaccine proteins for a
multi-subunit vaccine.
In conclusion, our vaccine showed partial efficacy and provided proof of the
principle that a TMV-based multi-subunit vaccine can be effective. Our results show
that a TMV-based vaccine could be administered with multiple doses without concerns
about side effects and toxicity. The TMV can have a dual function as antigen carrier as
well as an enhancer of immune response. Taken together, TMV can serve as a suitable
platform to deliver Pseudomonas aeruginosa proteins.
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